5-Amino-1MQ Doses Used in Published Studies: What Researchers Reported

Two of the most common search phrases around this molecule are "5-amino-1MQ dosage per day" and "5-amino-1MQ dosage subcutaneous." Both phrasings assume that somewhere in the literature there is a human dose range, a schedule, and a route that has been tested and reported. That assumption is worth examining directly, because the published research base for nicotinamide N-methyltransferase (NNMT) inhibition is preclinical — cultured cells and rodent models — and the questions those studies were designed to answer were mechanistic, not dose-finding in people.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing below is a protocol, a schedule, or a suggested amount, and no dosage chart appears on this page.

What 5-Amino-1MQ is in the language of the literature

5-Amino-1MQ belongs to a family of small-molecule inhibitors of NNMT, an enzyme that methylates nicotinamide and sits at a junction of NAD⁺ metabolism and one-carbon metabolism. Most of the published work in this space is written from the enzyme outward: researchers were asking what happens to tumour biology, adipose tissue, or metabolic phenotypes when NNMT activity is reduced, rather than asking what quantity of a compound a person might take. That framing matters for anyone reading a search result, because a paper can be highly informative about a pathway while containing nothing that functions as a dose recommendation.

Study by study: species, model and what researchers reported

Cell-culture work in HeLa cells

A 2021 report in Journal of Obstetrics and Gynaecology examined a small-molecule inhibitor of nicotinamide N-methyltransferase and reported anti-proliferative activity in HeLa cells. This was in vitro work: the compound was applied to cultured cervical cancer cells, and the outcome measured was the effect on cell proliferation, as the study described. Because the experimental system was a dish of cells bathed in medium, the exposure variable in such work is a concentration — an amount of compound per volume of culture medium — not a milligram amount given to an organism. There is no route of administration in a cell-culture experiment, no daily schedule, and no duration expressed in weeks of treatment in a living animal. Readers looking for "mg per day" will not find that quantity in this kind of study because the design never contained it.

NNMT inhibition combined with reduced calorie diet in diet-induced obese mice

A 2022 paper in Scientific Reports examined NNMT inhibition alongside a reduced calorie diet and reported that the combination established a distinct microbiome in diet-induced obese (DIO) mice. The species was the mouse; the model was diet-induced obesity, meaning animals were made obese on a high-fat diet before intervention; and the primary readout that the study reported was gut microbial community composition rather than a clinical endpoint. The important structural point for readers is that this was a combination design: diet restriction plus enzyme inhibition. When two interventions are applied together, the contribution of each to the reported microbiome shift cannot be extracted from the headline result, and a reader cannot infer what the inhibitor alone would have done — let alone what any amount would do in a human.

Mechanistic work on NNMT in the tumour microenvironment

A 2024 paper in Journal for ImmunoTherapy of Cancer examined NNMT in cancer-associated fibroblasts and reported that the enzyme drove tumour progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. The orientation here is target biology: the researchers described a role for NNMT within the tumour microenvironment and its influence on immune cell behaviour, as the study reported. Work of this kind builds the rationale for why an NNMT inhibitor might be developed at all, but it is not a dosing study, and it does not establish a safe or effective exposure for any species.

The published record at a glance

Why this page does not print milligram figures

PeptideU restricts what it states to what the cited literature supports at the level a reader can verify. Precise exposure quantities in preclinical papers live in methods sections, are specific to a formulation, a vehicle, a strain of animal and an experimental question, and are frequently reported as milligrams per kilogram of body weight rather than as a fixed human amount. Reproducing such a number outside that context turns a methods detail into something it was never meant to be: an implied instruction. The phrase "dosage per day" does not exist in this literature as a human parameter, and a page that manufactured one would be inventing data rather than summarising it.

Anyone who wants the exact experimental quantities used in a given paper can read that paper's methods section directly through the links in the references below. What they will find is a laboratory parameter, described by researchers for other researchers, and interpreted only within the model the study used.

Why a study dose does not translate into a recommendation

Even when a rodent exposure is published, several barriers separate it from a human amount. These are the standard reasons pharmacologists treat cross-species extrapolation with caution:

• Body-surface-area and metabolic scaling. Mice metabolise many compounds far faster than humans per unit of body weight, so a milligram-per-kilogram figure in a mouse does not map onto the same figure in a person.
• Route differences. Oral gavage, intraperitoneal injection, diet admixture and subcutaneous delivery produce different absorption, peak concentrations and tissue distribution for the same nominal amount.
• Model-specific biology. A diet-induced obese mouse on a restricted diet is a designed metabolic state, as described in the 2022 microbiome study; the reported result belongs to that state, not to an untested human population.
• In vitro concentrations are not doses. The micromolar exposures that characterise cell-culture pharmacology, such as the system used in the HeLa cell report, cannot be converted into a body-weight amount because absorption, protein binding, metabolism and clearance are absent from a dish.
• Endpoint mismatch. Reported endpoints such as microbial community structure, cell proliferation, or macrophage phenotype in the bladder cancer work are not the outcomes people typically search for, and an exposure optimised for one endpoint says nothing about another.
• No published human dose-ranging data. Phase I dose-escalation studies are what generate tolerated human ranges; the verified literature summarised here does not include such work.

About the "subcutaneous" search phrasing

The search "5-amino-1MQ dosage subcutaneous" presupposes both a route and a quantity. Route of administration in preclinical research is chosen for experimental convenience and pharmacokinetic reasons — to bypass first-pass metabolism, to achieve a defined exposure, or to match a prior study's design. It is not evidence that the same route is appropriate, tolerated, or bioavailable in humans. None of the three verified papers summarised here was a human route-comparison or bioavailability study, and none of them reported a human subcutaneous exposure. Where a molecule's route has not been characterised in people, the literature simply does not answer the question the search is asking.

Adverse Events in the 5-Amino-1MQ Literature: What Studies Report

The verified papers available here were designed around mechanism and efficacy-style endpoints rather than around safety surveillance, and their reported outcomes were, respectively, anti-proliferative activity in cultured cells (2021), a distinct microbiome in diet-induced obese mice under combined diet restriction and NNMT inhibition (2022), and NNMT-driven tumour progression and immunotherapy resistance through macrophage modulation in urothelial bladder cancer (2024). None of these constitutes a human safety dataset. In practical terms, that means there is no published catalogue of human adverse events, no reported incidence rates, and no tolerability profile for this compound class in people within the literature cited here. Absence of reported harms in mechanistic preclinical work is not evidence of safety; it reflects that safety was not the question being asked.

A further nuance from the cancer literature is worth noting for interpretation rather than for practice: because the 2024 study described NNMT as an enzyme with an active role in tumour biology and immune modulation, inhibiting it is a biologically consequential act with effects that extend beyond any single tissue. That is a reason for research caution, not a basis for personal extrapolation.

What would have to exist before a human range could be described

1. Published pharmacokinetic data in humans, describing absorption, half-life and clearance by route.
2. Dose-escalation safety studies identifying tolerated exposures and dose-limiting effects.
3. Controlled trials linking a defined exposure to a defined clinical endpoint.
4. Independent replication across more than one research group and population.

Until studies of that type are published and indexed, any number circulating as a "5-Amino-1MQ daily dose" is not derived from the peer-reviewed record summarised here. Regulatory status is a separate matter from evidence: research chemicals supplied for laboratory use are labelled research-use-only and are not approved drug products, which is a reflection of exactly this evidentiary gap.

How to read a dosing search result critically

When a page presents a confident milligram figure, three questions usually clarify its provenance: which study is cited in the same sentence as the number; whether that study was conducted in humans, animals or cells; and whether the endpoint the study measured is the one the reader cares about. Applying those questions to the literature here returns a consistent answer — the reported work is preclinical and mechanistic, the outcomes concern cell proliferation, microbiome composition and tumour-microenvironment biology, and the study designs did not include human dosing. Readers with a clinical interest in NAD⁺ metabolism or NNMT biology are best served by discussing the published evidence with a licensed physician, who can weigh it against an individual medical history.

References

• NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (Journal for ImmunoTherapy of Cancer, 2024)
• Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (Journal of Obstetrics and Gynaecology, 2021)
• Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Scientific Reports, 2022)